Briacell Therapeutics Corp

BriaCell Therapeutics has opened its first Canadian clinical site for its pivotal Phase 3 study of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer, with Sunnybrook’s Odette Cancer Centre in Toronto joining the trial. The study now has over 80 active sites across 15 US states, including Penn Medicine, Mayo Clinic, and Yale, and is evaluating overall survival compared with physician’s choice. An interim analysis is planned after 144 patient deaths, and the trial recently received a positive DSMB recommendation to continue. BriaCell reported positive Phase 2 survival data at ASCO 2026, and the Bria-IMT combination regimen holds FDA Fast Track designation.

BriaCell Therapeutics has arranged a manufacturing deal with FUJIFILM Biotechnologies California to support the ongoing pivotal Phase 3 study and potential future commercial supply of its lead candidate Bria-IMT, an off-the-shelf allogenic cell therapy for metastatic breast cancer. The arrangement provides manufacturing capacity for the remainder of the Phase 3 trial and offers commercial scalability potential. Bria-IMT is currently being evaluated in combination with an immune checkpoint inhibitor in advanced metastatic breast cancer. BriaCell's President and CEO William V. Williams called the deal a key milestone in the development and commercialization strategy for the novel immunotherapy.

BriaCell Therapeutics has engaged Charles River Associates and Kaleio to support commercial strategy, market access evaluation, and brand planning for its immunotherapy candidate Bria-IMT. Charles River Associates will evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the US, while Kaleio will support brand strategies and customized commercial-readiness solutions. Bria-IMT is currently being evaluated in BriaCell’s ongoing pivotal Phase 3 study in metastatic breast cancer and is not yet commercially approved. The company described the engagements as a prudent commercial-readiness step as it prepares for potential future commercialization planning and strategic discussions, subject to successful clinical development and regulatory approvals.

BriaCell Therapeutics has entered into a Memorandum of Understanding with Uneedle to support the commercial readiness of Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administration. The non-binding agreement outlines plans to scale Uneedle’s microneedle devices for potential commercial quantities, contingent upon regulatory approval of Bria-IMT. Uneedle’s technology is already being used in BriaCell’s ongoing pivotal Phase 3 study of Bria-IMT in advanced metastatic breast cancer. BriaCell believes the approach may enable faster, more convenient administration and a more patient-friendly treatment experience.